HEMADY

Peak

dexamethasone

NDAORALTABLET
Approved
Oct 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

Corticosteroid Hormone Receptor Agonists

Pharmacologic Class:

Corticosteroid

Clinical Trials (5)

NCT07175415Phase 1/2Not Yet Recruiting

HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Started Oct 2026
42 enrolled
Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory+2 more
NCT07285239Phase 3Not Yet Recruiting

Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

Started May 2026
500 enrolled
Multiple Myeloma
NCT07224672Phase 2Not Yet Recruiting

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis

Started Mar 2026
60 enrolled
Amyloidosis
NCT07348393Phase 2Not Yet Recruiting

A Phase 2, Single Arm Multicenter, Study Testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Started Feb 2026
70 enrolled
Relapsed or Refractory Multiple Myeloma (RRMM)
NCT07095452Phase 2/3Recruiting

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Started Jan 2026
660 enrolled
Multiple Myeloma

Loss of Exclusivity

LOE Date
Dec 18, 2037
143 months away
Patent Expiry
Dec 18, 2037
Exclusivity Expiry
Oct 3, 2026

Patent Records (2)

Patent #ExpiryTypeUse Code
10537585
Dec 18, 2037
Product
11304961
Dec 18, 2037
Product
U-3344